Several GLP-1 and glucagon receptor dual agonists, including cotadutide, SAR425899, JNJ-64565111 and mazdutide, showed overall favourable safety profiles and varying body weight loss efficacy in individuals with overweight or obesity. This evidence concerns the gene GCGR and obesity disorder.